PRN Share Price | Profound Medical Corp. Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

28.89 k

Shareholding (Sep 2025)

FII

28.38%

Held by 75 FIIs

DII

64.04%

Held by 9 DIIs

Promoter

0.00%

Compare Profound Medical Corp. with Similar Stocks

Opsens, Inc.Spectral Medical, Inc.Perimeter Medical Imaging AI, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

NET SALES(Q) At CAD 3.06 MM has Fallen at -25.91%
OPERATING CASH FLOW(Y) Lowest at CAD -48.56 MM
ROCE(HY) Lowest at -106.37%

Risky -

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CAD 350 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.62

Return on Equity

-123.00%

Price to Book

7.83

Revenue and Profits:

Net Sales:

3 Million

(Quarterly Results - Jun 2025)

Net Profit:

-22 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

23.49%

6 Months

39.01%

1 Year

13.95%

2 Years

-10.23%

3 Years

-35.6%

4 Years

-11.65%

5 Years

-68.15%

Profound Medical Corp. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Profound Medical Corp. Hits Day High with 8.12% Surge in Stock Price

Profound Medical Corp. has seen a significant increase in its stock price today, contrasting with the modest rise of the S&P/TSX 60 index. Despite recent gains, the company faces ongoing challenges, including a substantial decline in profits over the past year and a negative return on equity.

Read full news article

Profound Medical Corp. Hits Day High with Strong 8.12% Intraday Surge

Profound Medical Corp. has seen significant short-term gains, with an 8.12% increase on November 11, 2025, and an 8.38% rise over the past week. However, the company faces long-term challenges, including a 20.75% decline over the past year and a 63.32% drop over five years.

Read full news article

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

17.89%

EBIT Growth (5y)

-184.70%

EBIT to Interest (avg)

-38.21

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.82

Sales to Capital Employed (avg)

0.20

Tax Ratio

0.01%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

47.63%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

4.48

EV to EBIT

-3.36

EV to EBITDA

-3.41

EV to Capital Employed

16.54

EV to Sales

12.02

PEG Ratio

Dividend Yield

ROCE (Latest)

-491.65%

ROE (Latest)

-106.03%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 5 Schemes (7.58%)

Foreign Institutions

Held by 75 Foreign Institutions (28.38%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -18.42% vs -34.48% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -40.91% vs -123.19% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "3.10",
          "val2": "3.80",
          "chgp": "-18.42%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-18.90",
          "val2": "-15.80",
          "chgp": "-19.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-21.70",
          "val2": "-15.40",
          "chgp": "-40.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-6,244.20%",
          "val2": "-4,260.20%",
          "chgp": "-198.40%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 50.52% vs 11.49% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.26% vs -2.41% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "14.60",
          "val2": "9.70",
          "chgp": "50.52%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-44.00",
          "val2": "-37.40",
          "chgp": "-17.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-38.10",
          "val2": "-38.20",
          "chgp": "0.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-3,095.70%",
          "val2": "-3,979.90%",
          "chgp": "88.42%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

3.10

3.80

-18.42%

Operating Profit (PBDIT) excl Other Income

-18.90

-15.80

-19.62%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-21.70

-15.40

-40.91%

Operating Profit Margin (Excl OI)

-6,244.20%

-4,260.20%

-198.40%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is -18.42% vs -34.48% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -40.91% vs -123.19% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

14.60

9.70

50.52%

Operating Profit (PBDIT) excl Other Income

-44.00

-37.40

-17.65%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-38.10

-38.20

0.26%

Operating Profit Margin (Excl OI)

-3,095.70%

-3,979.90%

88.42%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 50.52% vs 11.49% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 0.26% vs -2.41% in Dec 2023

All Annual Results

Company CV

About Profound Medical Corp.

Profound Medical Corp.

Pharmaceuticals & Biotechnology

Profound Medical Corp. is a commercial-stage medical device company. focused on customizable, incision-free therapies which combine real-time magnetic resonance imaging (MRI), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue. The Company’s products include TULSA-PRO System and SONALLEVE. The TULSA-PRO is used to ablate benign or malignant prostate tissue in patients with a variety of prostate diseases. Prostate diseases include prostate cancer and benign prostatic hyperlasia (BPH). Prostate cancer is one of the common types of cancer affecting men. TULSA-PRO and SONALLEVE share the common technological concept of using MRI to enable visualization of the surgeon desired tissue in real time. Both products also use thermal ultrasound technology to heat and ablate tissue.

Company Coordinates

Company Details

2400 Skymark Ave Unit 6 , MISSISSAUGA ON : L4W 5K5

Tel: 1 647 47613501 647 8724849

http://www.profoundmedical.com

Registrar Details